<DOC>
	<DOCNO>NCT01319279</DOCNO>
	<brief_summary>The purpose study : 1 . To assess pharmacokinetics hydrocodone bitartrate extended-release tablet subject moderate hepatic impairment subject normal hepatic function . 2 . To assess safety tolerability hydrocodone bitartrate extended-release tablet subject moderate hepatic impairment subject normal hepatic function .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Hydrocodone Extended-Release Tablet ( CEP-33237 ) Subjects With Normal Hepatic Function Subjects With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>1 . All subject : Written inform consent obtain 2 . Subjects normal hepatic function : The subject generally good health ( ageappropriate ) determine medical psychiatric history , physical examination , ECG , serum chemistry , hematology , coagulation , urinalysis , serology . 3 . Subjects hepatic impairment : The subject 's health otherwise clinically stable determined medical history , physical examination , ECG , serum chemistry , hematology , coagulation parameter ( PT , activate partial thromboplastin time [ aPTT ] , international normalize ratio [ INR ] ) , urinalysis , serology except sign symptom attributable liver disease . The subject case record note demonstrate physical sign consistent 1 follow characteristic clinical manifestation liver cirrhosis : liver firmness palpation , splenic enlargement , spider angioma , palmar erythema , parotid hypertrophy , testicular atrophy , ascites ( accumulation fluid abdominal cavity ) , gynecomastia . The subject ChildPugh Classification score 79 point ( moderate ) . 1 . All subject : The subject clinically significant , uncontrolled medical condition . The subject poor metabolizer CYP2D6 substrates base genotyping performed screening . The subject previously participate study CEP33237 . The subject know sensitivity idiosyncratic reaction hydrocodone hydromorphone , related compound , metabolite , compound list present study formulation . 2 . Subjects normal hepatic function : The subject positive test result HBsAg antibody hepatitis C. The subject history alcohol , narcotic , substance abuse . 3 . Subjects hepatic impairment : The subject severe ascites . The subject acute exacerbation liver disease indicate worsen clinical sign hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Hydrocodone</keyword>
	<keyword>Extended Release</keyword>
	<keyword>Hepatic impairment</keyword>
</DOC>